

type of report	Current report
number	68/2012
company	PHARMENA

Share capital increase of Cortria Corporation

The Management Board of PHARMENA S.A. informs that on 19th October 2012, the Issuer increased share capital of subsidiary company Cortria Corporation by 1,000,000 USD (through issue of 10,000 new shares). The share capital increase is financed from the Issuer's own funds obtained from the issue of series C shares.

The goal of the issue is to finance:

- a) production of tablets containing 1-MNA for phase II clinical trials ("Proof of Concept") of innovative anti-atherosclerosis medicinal product (1-MNA),
- b) bioavailability testing of innovative anti-atherosclerosis medicinal product (1-MNA),
- c) current operations of Cortria (patent fees, legal services, patent services, accounting services).

The production of tablets containing 1-MNA for phase II clinical trials, as well as bioavailability testing are indispensable for carrying phase II clinical trials (on people) of anti-atherosclerosis medicinal product (1-MNA). The research will be conducted by Cortria Corporation in Canada.

Cortria Corporation is a private pharmaceutical company with registered headquarters in USA, which conducts clinical trials focusing on developing safe and well-tolerated medicinal products for the treatment of cardiovascular diseases, particularly atherosclerosis.

The information is made public due to the fact that the production of tablets for phase II clinical trials and conducting bioavailability testing of 1-MNA medicinal product is essential for carrying out phase II clinical trials on anti-atherosclerosis medicinal product and commercialisation of this project. Potential revenue resulting from the commercialisation of anti-atherosclerosis medicinal product may have significant influence on the Issuer's financial and economic situation.

Legal basis: Alternative Trading System Rules – Exhibit 3 "Current and Periodical Information in the Alternative Trading System on the NewConnect Market", Article 3 (1).

Representatives of the company:

- Konrad Palka - President of the Board
- Marzena Wieczorkowska – Vice President of the Board